Alligator Bioscience

The updated dividend policy reads as follows:

Alligator will continue to focus on further developing its project portfolio and pursue partnerships for, or the sale of, its projects. Should Alligator receive significant proceeds from such events, the Board’s intention is to propose that the proceeds, save for any funds deemed necessary for working capital and activities deemed value enhancing for all shareholders, will be distributed to the shareholders of Alligator in the form of a dividend or repurchase of shares. In its proposal, the Board will consider Alligator’s strategy, objectives and third-party commitments in force at any given time, as well as applicable limitations in the Swedish Companies Act.

“The updated dividend policy reflects our sharpened strategic and operational focus, aimed at enabling the continued development and partnering of mitazalimab. Thus, the policy ensures that the capital structure is fully aligned with our long-term priorities,” said Hans-Peter Ostler, Chairman of the Board.